ALDH1A1 and lung adenocarcinoma: In summary, we found that erlotinib-resistant lung adenocarcinoma cells depended on ALDH1A1 and that ALDH1A1 conferred EMT and drug resistance by facilitating the ROS-RCS metabolic pathway and by activating GPX4 and SOD2 transcription.